Ascendis Pharma A/S (ASND) Downgraded by BidaskClub to “Sell”

BidaskClub cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning.

A number of other research analysts also recently weighed in on the company. Wedbush set a $79.00 price target on Ascendis Pharma A/S and gave the company a buy rating in a report on Thursday, August 30th. Stifel Nicolaus lowered their price target on Ascendis Pharma A/S from $85.00 to $81.00 and set a buy rating on the stock in a report on Thursday, August 30th. Canaccord Genuity began coverage on Ascendis Pharma A/S in a report on Tuesday, August 7th. They set a buy rating and a $81.00 price target on the stock. ValuEngine downgraded Ascendis Pharma A/S from a strong-buy rating to a buy rating in a report on Tuesday, October 2nd. Finally, Wells Fargo & Co lifted their price target on Ascendis Pharma A/S from $83.00 to $88.00 and gave the company an outperform rating in a report on Thursday, August 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. Ascendis Pharma A/S has an average rating of Buy and an average price target of $77.25.

Shares of NASDAQ ASND opened at $59.84 on Tuesday. The firm has a market capitalization of $2.96 billion, a P/E ratio of -13.82 and a beta of 0.68. Ascendis Pharma A/S has a 52-week low of $31.56 and a 52-week high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, August 29th. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.03) by $0.37. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 49.69% and a negative net margin of 17,641.85%. Analysts anticipate that Ascendis Pharma A/S will post -4.22 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Orbimed Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 31.1% during the second quarter. Orbimed Advisors LLC now owns 4,413,291 shares of the biotechnology company’s stock valued at $293,572,000 after buying an additional 1,045,976 shares in the last quarter. Sofinnova Ventures Inc purchased a new position in shares of Ascendis Pharma A/S during the first quarter valued at $162,160,000. venBio Select Advisor LLC grew its holdings in shares of Ascendis Pharma A/S by 22.7% during the first quarter. venBio Select Advisor LLC now owns 2,063,336 shares of the biotechnology company’s stock valued at $134,942,000 after buying an additional 382,312 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Ascendis Pharma A/S by 25.4% during the first quarter. Millennium Management LLC now owns 665,727 shares of the biotechnology company’s stock valued at $43,539,000 after buying an additional 134,936 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Ascendis Pharma A/S by 8.1% during the second quarter. BlackRock Inc. now owns 438,789 shares of the biotechnology company’s stock valued at $29,188,000 after buying an additional 32,980 shares in the last quarter. Institutional investors and hedge funds own 94.56% of the company’s stock.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Google Finance Portfolio Workaround

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply